International Peer Reviewed Publications

    1. Abdel-Wahab M, Esmat G, Milad M, Abdel Razek S, Strickland G, (1989): Characteristic sonographic pattern of schistosomal hepatic fibrosis. Am J Trop Med Hyg; 40(1):72-6.
    2. Abdel-Wahab M, Esmat G, Narooz S, Yosery A,  Struewing J,  Strickland G, (1990): Sonographic studies of school children in a village endemic for Schistsoma mansoni. Transactions of the Royal Society Tropical Medicine; 88:69-73.
    3. Abdel-Wahab M, Esmat G, (1992): The value of Ultrasonography in assessment of portal hypertension in hepatosplenic Schistosomiasis. Mem. Inst. Oswaldo Cruz, Rio de Janerio;87 suppl. IV, pp. 143-7.
    4. Abdel-Wahab G, Esmat G, Strickland G, (1992): Grading of Hepatic Schistosomiasis by the use of ultrasonography.  Am J Trop Med Hyg; 46(4): 403-8.
    5. Abdel-Wahab M, Esmat G, Ramzy I, Fouad R, Abdel-Rahman M, Yosery A, Narooz S, Strickland G, (1992): Schistosoma haematobium infection Egyptian school children: Demonstration of both hepatic and urinary tract morbidity by ultrasonography. Transactions of the Royal Society of Tropical Medicine and Hygiene; 86(4): 406-9.
    6. Bassily S, Strickland G, Abdel-Wahab M, Esmat G,  Narooz S, El-Masr N, Constantine N, Pstruewing J, (1992): Efficacy of Hepatitis “B” vaccination in primary school children from village endemic for Schistosoma mansoni. Rio de Jenerio; vol. 87 suppl. IV:143-7.
    7. Abdel-Wahab M, Ramzy I, Esmat G,  El-Kaffas H, Strickland G, (1992): Ultrasound of detecting Schisotosma haematobium urinary tract complications comparison with Radiographic procedures. The Journal of Urology; 148: 346-50.
    8. Abdel-Wahab M, Esmat G, Farag A, El-Borey Y, Strickland G, (1993): Ultrasonographic predictions of esophageal varices in Schistosoma mansoni. Am J of Gastroenterology; 88(4), 560-3.
    9. Abdel-Wahab M, Yosery A, Narooz S, Esmat G, El Hak S, Nasif S, Strickland G, (1993): Is Schistosoma mansoni replacing Schistosoma haematobium in Fayoum? Am J Trop Med Hyg; 49(6): 560-3.
    10. Abdel- Wahab M, Zakaria S, Kamel M, Abdel Khalq M, Mabrouk M, Salama H, Esmat G, Thomas D, Strickland G, (1994): High seroprevelance of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg; 51(5):563-7
    11. Kamel M, Miller F, El-Masry A, Zakaria S, Khatab M, Esmat G, Ghaffar Y, (1994): Epidemiology of Schistosoma mansoni, hepatitis “B” and Hepatitis  “C” infections in Egypt. Annals of Tropical Medicine and Parasitology; 88:501-9.
    12. Bakr A, Khalil M, Esmat G, (1997): Acute cholecystitis is an indication for laparoscopic cholecystectomy: a prospective study. JSLS; 1:119-124.
    13. Abdel Wahab M, Esmat G, El Boraey Y, Ramzy I, Medhat E, Stuckland S, (2000): The epidemiology of schistosomiasis in Egypt: methods, training and quality control of clinical and ultrasound examinations. American J of Tropical Medicine and Hygiene; 62(2):17-20.
    14. Abdel Wahab M, Esmat G, Medhat E,  Narooz S, Ramzy I, El Boraey Y,  Stuckland S, (2000): The epidemiology of schistosomiasis in Egypt: Menofia governarate. American J of Tropical Medicine and Hygiene; 62(2):28-34.
    15. Abdel Wahab M, Esmat G, Ramzy I, Narooz S, Medhat E,  Ibrahim M,  El Boraey Y,  Strickland S, (2000): The epidemiology of schistosomiasis in Egypt: Fayoum governarate. American J of Tropical Medicine and Hygiene; 62(2):55-64.
    16. Strickland GT, Elhefni H, Salman T, Waked I, Abdel-Hamid M, Mikhail N, Esmat G, Fix A, (2002): Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg; 67(4):436-42.
    17. Esmat G, Abouzied A, Mohamed MK, Abdel-Hamid M, Elrazki MS, Ismail SA, Abdel Aziz F, Mikhail N, Fix A, Strickland GT, Sjogren M, (2002): Treatment with Peg Interferon alpha 2-b (PEG INF) plus ribavirin compared to Interferon alpha-2b (INF alfa-2b) plus Ribavirin on subjects with chronic hepatitis C infected with HCV genotype 4 . Hepatology; 36(4):364A.
    18. Esmat G, Zakaria S, Khatab H, Abdel-Hamid M, Anwar M, Elrazki MS, El-Daly M, Elkafrawi S, Hasan A, Shaheen A,  Ismail SA,  Sjogren M Abouzied A, (2002): Impact of hepatitis C virus (HCV) genotype and viral load on the biochemical and histopathological liver profiles in Egyptian patients infected with HCV. Hepatology; 36(4):535A.
    19. Esmat G, Abouzied AM, Ismail A, Saleh SM, Said M, Anwar M, Abdel Aziz F, Shaheen A, Ahmed RA, Abdel Hamid M, Zalata KR, Fix AD, Strickland T, Sjogren M, (2002): Treatment with peg-interferon alfa-2b (peg-inf) plus ribavirin compared to interferon alfa-2b (ifn alfa 2b) plus ribavirin on subjects with chronic hepatitis c infected with HCV genotype 4.  Tropical Medicine and Hygiene; Vol. 67 No. 2:131-132.
    20. Esmat G, Abouzied AM, Abdel-Aziz F, Mohamed MK, Abdel-Hamid M, El Raziky MS, Ismail SA, K R Zalata, Mikhail NN, (2002): Treatment with peg-interferon alfa-2b (PEG-Ifn) plus ribavirin compared to interferon alfa-2b (INF alfa-2b) plus ribavirin on subjects with chronic hepatitis c infected with HCV genotype 4.   Hepatology; Vol. 36, No. 4, pt 2 of 2:364A.
    21. Emsat G, Mohamed MK, Abdel Hamid M, Zalata K, Khatab H, El Batanony M, Abouzied MA, El Raziky M, Shaheen AM, Ismail A, Strickland GT, Fix A, Sjogren M, (2003):  The impact of steatosis on baseline characteristics and end of treatment response for chronic hepatitis (C) genotype 4 patients treated with interferon.Journal of Hepatology; 38, Suppl. 2:139.
    22. Esmat G, Al Raziky M, Abouzied A, Kamal M, Abdel Hamid M, Abdel Aziz F, Shaheen AA, Mikhail N, Strickland T, Sjogren M, (2003): Impact of schistosomal infection on interferon response in genotype 4 chronic hepatitis C patients. Viral Hepatitis and Liver disease, Sydney; Page 153.
    23.  Esmat G, Abouzied A, Abdel-Hamid M, Mohamed MK, Zalata K, El Raziky ME, Ismail SA, Said M, Hasan A, Anwar M, Shaheen A, Abdel ziz F, Mikhail NN, Ismail A, Fix A, Strickland TG, Sjogren MH, (2003): Results of a randomized clinical trial of genotype 4 infected subjects when treated with standard or pegylated interferon alfa-2b in combination with ribavirin. Hepatology; 38, No. 4, Suppl. 1:314A.
    24. El Raziky MS, El-Hawary M, El- Koofy N, Okasha S, Kotb M, Salama K, Esmat G, El- Raziky M,  Abouzied MA, El Karaksy H, (2004): Hepatitis C virus infection in Egyptian children: Single center experience. Journal of Viral Hepatitis; 11:471-6.
    25. Nada O, Abdel-Hamid M, Ismail A, El-Shabrawy L, Sidhom K, El-Badawy N, Ghazal F, El-Daly M, El-Kafrawy S, Esmat G, Loffredo CA, (2005): The role of the tumor necrosis factor (TNF)-Fas L and HCV in the development of hepatocellular carcinoma, Journal of Clinical Virology; 34, Issue 2:140-146.
    26. Esmat G, Yosry A, El-Serafi M, Omar A, Doss W, Hosny A, Ghali A, Sabry H, Attia H, Kamel S, Said M, Gabali H, Lee SK, Tanaka K, (2005): Donor outcomes in right lobe adult living donor liver transplantation: single-center experience in Egypt.Transplant Proc; 37(7):3147-50.
    27. Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S, Esmat G, Hamid MA, Mohamed MK, Fontanet A, (2006): Higher clearance of hepatitis C virus infection in females compared with males. Gut; 55(8):1183-7.
    28. Mohamed MK, Bakr I, El-Hoseiny M, Arafa N, Hassan A, Ismail S, Anwar M, Attala M, Rekacewicz C, Zalata K, Abdel-Hamid M, Esmat G, Fontanet A, (2006): HCV-related morbidity in a rural community of Egypt. Med Virol; 78(9):1185-9. 
    29. Zakaria S, Fouad R, Shaker O, Zaki S, Hashem A, El-Kamary SS, Esmat G, (2007): Changing patterns of acute viral hepatitis at a major urban referral center in Egypt  Clin Infect Dis; 44(4):e30-6.
    30. Esmat G, Metwally M, Zalata KR, Gadalla S, Abdel-Hamid M, Abouzied A, Shaheen AA, El-Raziky M, Khatab H, El-Kafrawy S, Mikhail N, Magder LS, Afdhal NH, Strickland GT, (2007): Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J hepatol; 46(4):620-7, Epub 2007 Jan 24. 
    31. Abdel-Hamid M, El-Daly M, Molnegren V, El-Kafrawy S, Abdel-Latif S, Esmat G, Strickland GT, Loffredo C, Albert J, Widell A, (2007): Genetic diversity in hepatitis C virus in Egyptand possible association with hepatocellular carcinoma. J gen virol.; 88(Pt 5):1526-31. 
    32. El-Raziky MS, El-Hawary M, Esmat G, Abouzied AM, El-Koofy N,Mohsen N, Mansour S, Shaheen A, Abdel Hamid M, El-Karaksy H, (2007): Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children, World J Gastroenterol.; 28, 13(12):1828-32. 
    33. El-Karaksy H, Nomachi S, Esmat G, El-Serafy M, Kamel RR, El-Ansary A, Refaat S, Tanaka K, (2007): Equal outcome of living-related liver transplantation for Wilson’s disease from heterozygote and nonheterozygote donors: A report of a brother and sister, Indian J Med Sci.; 61(5):286-8. 
    34. El-Hawary MA, El-Raziky MS, Esmat G, Soliman H, Abouzied A, El-Raziky M, El-Akel W, El-Sayed R, Shebl F, Shaheen AA, El-Karaksy H, (2007): Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt. World J Gastroenterol.; 13(20):2846-2851.
    35. Zekri AR, Haleem HA, Esmat G, Bahnassy AA, El-Din HM, Hafez MM, Sharaby AF, Sharaf H, Zakaria MS, (2007): Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4. J Viral Hepat.; 14(7):468-77.
    36. Males S, Gad RR, Esmat G, Abobakr H, Anwar M, Rekacewicz C, El Hoseiny M, Zalata K, Abdel-Hamid M, Bedossa P, Pol S, Mohamed MK, Fontanet A, (2007): Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C. Antiviral Therapy; 12:797-803.
    37. Tabll AA, Khalil SB, El-Shenawy RM, Esmat G, Helmy A, Attallah A, El-Awady MK, (2008): Establishment of Hybrid Cell Lines Producing Monoclonal Antibodies to a Synthetic Peptide from the E1 Region of the Hepatitis C Virus. Journal of Immunoassay & Immunochemistry; 29:91-104.
    38. Yosry A, Abdel-Rahman M, Esmat G, El-Serafy M, Omar A, Doss W, Zayed N, Said M, Ismail T, Hosny A, Marawan E, El-Malt O, Kamel RR, Hatata Y, El-Taweel A, Ghali A, Sabri H, Kamel S, El-Gabaly H, (2009): Recurrence of hepatitis C virus (genotype 4) infection after living-donor liver transplant in Egyptian patients. Exp Clin Transplant.; 7(3):157-63.
    39. Esmat G, El Akel W, Metwally M, Soliman A, Doss W, Hamid MA, Kamal M, Zalata K, Khattab H, El-Kassas M, Esmat M, Hasan A, El-Raziky M, (2009): Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss. Indian J Gastroenterol.; 28(2):45-8.
    40. Shiha G, Sarin SK, Ibrahim AE, Omata M, Kumar A, Lesmana LA, Leung N, Tozun N, Hamid S, Jafri W, Maruyama H, Bedossa P, Pinzani M, Chawla Y, Esmat G, Doss W, Elzanaty T, Sakhuja P, Nasr AM, Omar A, Wai CT, Abdallah A, Salama M, Hamed A, Yousry A, Waked I, Elsahar M, Fateen A, Mogawer S, Hamdy H, Elwakil R, (2009): Jury of the APASL Consensus Development Meeting 29 January 2008 on Liver Fibrosis With Without Hepatitis B or C. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int.; 3(2):323-33.
    41. El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK, (2009): Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol.; 81(9):1576-83.
    42. El-Kamary SS, Shardell MD, Abdel-Hamid M, Ismail S, El-Ateek M, Metwally M, Mikhail N, Hashem M, Mousa A, Aboul-Fotouh A, El-Kassas M, Esmat G, Strickland GT. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine. 2009 May;16(5):391-400
    43. El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK:Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol. 2009 Sep;81(9):1576-83. 
    44. Shiha G, Sarin SK, Ibrahim AE, Omata M, Kumar A, Lesmana LA, Leung N, Tozun N, Hamid S, Jafri W, Maruyama H, Bedossa P, Pinzani M, Chawla Y, Esmat G, Doss W, Elzanaty T, Sakhuja P, Nasr AM, Omar A, Wai CT, Abdallah A, Salama M, Hamed A, Yousry A, Waked I, Elsahar M, Fateen A, Mogawer S, Hamdy H, Elwakil R: Jury of the APASL Consensus Development Meeting 29 January 2008 on Liver Fibrosis With Without Hepatitis B or C. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int. 2009 Jun;3(2):323-33. 
    45. Yosry A, Abdel-Rahman M, Esmat G, El-Serafy M, Omar A, Doss W, Zayed N, Said M, Ismail T, Hosny A, Marawan E, El-Malt O, Kamel RR, Hatata Y, El-Taweel A, Ghali A, Sabri H, Kamel S, El-Gabaly H: Recurrence of hepatitis C virus (genotype 4) infection after living-donor liver transplant in Egyptian patients. Exp Clin Transplant. 2009 Sep;7(3):157-63.
    46. Zekri AR, Moharram RA, Mohamed WS, Bahnassy AA, Alam El-Din HM, Abo-Shadi MM, Zayed NA, El-Magzangy H, Abdel-Aziz AO, Esmat G.: Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1. Eur J Gastroenterol Hepatol. 2010 Apr;22(4):450-6.
    47. El-Karaksy HM, Anwar G, Esmat G, Mansour S, Sabry M, Helmy H, El-Hennawy A, Fouad H: Prevalence of hepatic abnormalities in a cohort of Egyptian children with type 1 diabetes mellitus. Pediatric Diabetes. 2010 Nov;11(7):462-70
    48. Zekri AR, Alam El-Din HM, Bahnassy AA, Zayed NA, Mohamed WS, El-Masry SH, Gouda SK, Esmat G: Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. Comp Hepatol. 2010 Jan 5;9(1)
    49. Mohammed RH, ElMakhzangy HI, Gamal A, Mekky F, El Kassas M, Mohammed N, Abdel Hamid M, Esmat G: Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians. Clin Rheumatol. 2010 Dec;29(12):1373-80.
    50. Mostafa A, Mohamed MK, Saeed M, Hasan A, Fontanet A, Godsland I, Coady E, Esmat G, El-Hoseiny M, Abdul-Hamid M, Hughes A, Chaturvedi N. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut. 2010 Aug;59(8):1135-40.
    51. Fathy A, Eldin MM, Metwally L, Eida M, Abdel-Rehim M, Esmat G. Interferon therapy shifts natural killer subsets among Egyptian patients with chronic hepatitis C. Braz J Infect Dis. 2010 Jul-Aug;14(4):398-405
    52. Bader el-Din NG, Abd el-Meguid M, Tabll AA, Anany MA, Esmat G, Zayed N, Helmy A, el-Zayady AR, Barakat A, el-Awady MK. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy. J Gastroenterol Hepatol. 2011 Jan;26(1):55-62.
    53. Hashem M, El-Karaksy H, Shata MT, Sobhy M, Helmy H, El-Naghi S, Galal G, Ali ZZ, Esmat G, Abdelwahab SF, Strickland GT, El-Kamary SS. Strong hepatitis C virus (HCV)-specific cell-mediated immune responses in the absence of viremia or antibodies among uninfected siblings of HCV chronically infected children. J Infect Dis. 2011 Mar 15;203(6):854-61
    54. Wiersma ST, McMahon B, Pawlotsky JM, Thio CL, Thursz M, Lim SG, Ocama P, Esmat G, Mendy M, Bell D, Vitoria M, Eramova I, Lavanchy D, Dusheiko G; World Health Organization Department of Immunization, Vaccines and Biologicals. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int. 2011 Jul;31(6):755-61. 
    55. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M, Esmat G, Guan R, Han KH, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011 Jul;31 Suppl 2:61-80
    56. Elhawary EI, Mahmoud GF, El-Daly MA, Mekky FA, Esmat GG, Abdel-Hamid M. Association of HCV with diabetes mellitus: an Egyptian case-control study. Virol J. 2011 Jul 26;8:367. 
    57. Esmat G, Hashem M, El-Raziky M, El-Akel W, El-Naghy S, El-Koofy N, El-Sayed R, Ahmed R, Atta-Allah M, Hamid MA, El-Kamary SS, El-Karaksy H. Risk factors for hepatitis C virus acquisition and predictors of persistence among Egyptian children. Liver Int. 2012 Mar;32(3):449-56.
    58. El-Ekiaby N, Hamdi N, Negm M, Ahmed R, Zekri AR, Esmat G, Abdelaziz AI. Repressed induction of interferon-related microRNAs miR-146a and miR-155 in peripheral blood mononuclear cells infected with HCV genotype 4. FEBS Open Bio. 2012 Jul 20;2:179-86.
    59. Abbas E, Shaker O, Abd El Aziz G, Ramadan H, Esmat G. Epidermal growth factor gene polymorphism 61A/G in patients with chronic liver disease for early detection of hepatocellular carcinoma: a pilot study. Eur J Gastroenterol Hepatol. 2012 Apr;24(4):458-63
    60. Mekky RY, Hamdi N, El-Akel W, Esmat G, Abdelaziz AI. Estrogen-related MxA transcriptional variation in hepatitis C virus-infected patients. Transl Res. 2012 Mar;159(3):190-6.
    61. Yosry A, Said M, Esmat G, Al-Serafy M, Omar A, Doss W, Omran D, Saad Y, Kamel S, Abdel-Bary A, Hatata Y, Hosny A. HLA tissue typing has no effect on the outcome of patients undergoing a living-donor liver transplant: a single-center experience in Egypt. Exp Clin Transplant. 2012 Apr;10(2):136-40.
    62. El-Shamy A, Shoji I, El-Akel W, Bilasy SE, Deng L, El-Raziky M, Jiang DP, Esmat G, Hotta H. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol. 2012 Dec;50(12):3886-92. 
    63. Mabrouk M, Esmat G, Yosry A, El-Serafy M, Doss W, Zayed N, El-Sahhar M, Awny S, Omar A. Health-related quality of life in Egyptian patients after liver transplantation. Ann Hepatol. 2012 Nov-Dec;11(6):882-90.
    64. Esmat G. Hepatitis C in the Eastern Mediterranean Region. East Mediterr Health J. 2013 Jul;19(7):587-8.
    65. Elalfy MS, Esmat G, Matter RM, Abdel Aziz HE, Massoud WA. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation. Ann Hepatol. 2013 Jan-Feb;12(1):54-61.
    66. Esmat G, El Kassas M, Hassany M, Gamil ME, El Raziky M. How to optimize HCV therapy in genotype 4 patients. Liver Int. 2013 Feb;33 Suppl 1:41-5.
    67. El-Kady NM, Esmat G, Mahmoud EH, Darweesh SK, Mahmoud SH, Elagawy WA. Hypertonic saline-enhanced radiofrequency versus chemoembolization sequential radiofrequency in the treatment of large hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2013 May;25(5):628-33.
    68. Khairy M, Abdel-Rahman M, El-Raziky M, El-Akel W, Zayed N, Khatab H, Esmat G. Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup. Hepat Mon. 2012 Nov;12(11):e6718
    69. Tayel SS, Helmy AA, Ahmed R, Esmat G, Hamdi N, Abdelaziz AI. Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus. Arch Virol. 2013 Aug;158(8):1755-64
    70. Abdel-Rahman M, Saad Y, El-Raziky M, Zayed N, El-Akel W, Said M, El-Beshlawy M, Esmat G. Hepatitis C genotype 4 with normal transaminases: correlation with fibrosis and response to treatment, a cohort Egyptian study of 4277 patients. Clin Res Hepatol Gastroenterol. 2013 Nov;37(5):479-84.
    71. Shaker O, Bassiony H, El Raziky M, El-Kamary SS, Esmat G, El-Ghor AM, Mohamed MM. Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4. Mediators Inflamm. 2013;2013:392746.
    72. Said ZN, Sayed MH, Salama II, Aboel-Magd EK, Mahmoud MH, Setouhy ME, Mouftah F, Azzab MB, Goubran H, Bassili A, Esmat GE. Occult hepatitis B virus infection among Egyptian blood donors. World J Hepatol. 2013 Feb 27;5(2):64-73.
    73. Ragab D, Laird M, Duffy D, Casrouge A, Mamdouh R, Abass A, Shenawy DE, Shebl AM, Elkashef WF, Zalata KR, Kamal M, Esmat G, Bonnard P, Fontanet A, Rafik M, Albert ML. CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients. Cytokine. 2013 Aug;63(2):105-12. 
    74. Abdel-Rahman M, El-Sayed M, El Raziky M, Elsharkawy A, El-Akel W, Ghoneim H, Khattab H, Esmat G. Coinfection with hepatitis C virus and schistosomiasis: fibrosis and treatment response. World J Gastroenterol. 2013 May 7;19(17):2691-6. 
    75. Khairy M, El-Raziky M, El-Akel W, Abdelbary MS, Khatab H, El-Kholy B, Esmat G, Mabrouk M. Serum autoantibodies positivity prevalence in patients with chronic HCV and impact on pegylated interferon and ribavirin treatment response. Liver Int. 2013 Nov;33(10):1504-9.
    76. Maklad S, Esmat G, Doss W, Abou-Zeid A, El-Din SS. Response and seroconversion rates among HBeAg-positive chronic HBV Egyptian patients treated with peginterferon alpha 2a (Pegasys), a single-centre experience. Arab J Gastroenterol. 2013 Jun;14(2):73-7.
    77. El Raziky M, Fathalah WF, El-Akel WA, Salama A, Esmat G, Mabrouk M, Salama RM, Khatab HM. The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study. Hepat Mon. 2013 May 28;13(5):e10069.
    78. Barsoum RS, Esmat G, El-Baz T. Human schistosomiasis: clinical perspective: review. J Adv Res. 2013 Sep;4(5):433-44. 
    79. Elbaz T, Esmat G. Hepatic and intestinal schistosomiasis: review. J Adv Res. 2013 Sep;4(5):445-52.
    80. Zekri AR, El-Kassas M, Saad Y, Bahnassy A, El-Din HK, Darweesh SK, Abdel Hafez H, Esmat G. Caspase recruitment domains. New potential markers for diagnosis of hepatocellular carcinoma associated with HCV in Egyptian patients. Ann Hepatol. 2013 Sep-Oct;12(5):774-81.
    81. El Raziky M, Attia D, El Akel W, Shaker O, Khatab H, Abdo S, Elsharkawy A, Esmat G. Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment. Arab J Gastroenterol. 2013 Sep;14(3):94-8
    82. Esmat G, Elsharkawy A, El Akel W, Fouad A, Helal K, Mohamed MK, Attia D, Khattab H, Doss W, Labib S. Fibroscan of chronic HCV patients coinfected with schistosomiasis. Arab J Gastroenterol. 2013 Sep;14(3):109-12.
    83. Esmat G, El Kassas M, Hassany M, Gamil M, El Raziky M. Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues. Liver Int. 2014 Feb;34 Suppl 1:24-8.
    84. Umar M, Khan AG, Abbas Z, Arora S, Asifabbas N, Elewaut A, Esmat G, Foster G, Fried M, Goh KL, Hamama TB, Imawari M, Isakov V, Krabshuis J, LaBrecque D, Lemair A, Malfertheiner P, Ryder S, Schiedermaier P, Stimac D, Tandon R, Villamil F, Zapata R, Ferenci P; World Gastroenterology Organisation. World Gastroenterology Organisation global guidelines: diagnosis, management and prevention of hepatitis C April 2013. J Clin Gastroenterol. 2014 Mar;48(3):204-17.
    85. Obach D, Deuffic-Burban S, Esmat G, Anwar WA, Dewedar S, Canva V, Cousien A, Doss W, Mostafa A, Pol S, Buti M, Siebert U, Fontanet A, Mohamed MK, Yazdanpanah Y. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt. Clin Infect Dis. 2014 Apr;58(8):1064-71
    86. Fawzy IO, Negm M, Ahmed R, Esmat G, Hamdi N, Abdelaziz AI. Tamoxifen downregulates MxA expression by suppressing TLR7 expression in PBMCs of males infected with HCV. J Med Virol. 2014 Jul;86(7):1113-9.
    87. Mabrouk M, El-Raziky M, Zayed N, Salama R, El-Akel W, Awad T, El Beshlawy M, Esmat G. Clinical, biochemical and pathological profiles of 5464 Egyptian chronic hepatitis C-infected patients. Hepatogastroenterology. 2013 Oct;60(127):1731-5.
    88. Cousien A, Obach D, Deuffic-Burban S, Mostafa A, Esmat G, Canva V, El Kassas M, El-Sayed M, Anwar WA, Fontanet A, Mohamed MK, Yazdanpanah Y. Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt. BMC Med Res Methodol. 2014 Mar 17;14:39.
    89. Maklad S, Esmat G, Hassan E, Attalah M, Zeid AA. Liver Biopsy and FibroScan to Detect Early Histopathological Changes in Chronic HBV Patients Not Candidate for Treatment. Gastroenterology Res. 2014 Apr;7(2):56-63.
    90. Alboraie M, Khairy M, Elsharkawy A, Elsharkawy M, Asem N, Abo El-Seoud AR, Elghamry FG, Esmat G. Egy-score as a noninvasive score for the assessment of hepatic fibrosis in chronic hepatitis C: a preliminary approach. 
    91. Esmat G, El Raziky M, Elsharkawy A, Sabry D, Hassany M, Ahmed A, Assem N, El Kassas M, Doss W. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. J Interferon Cytokine Res. 2015 Jan;35(1):49-54. 
    92. Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015 Jun;64(6):948-56. 
    93. Waked I, Doss W, El-Sayed MH, Estes C, Razavi H, Shiha G, Yosry A, Esmat G. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol. 2014 Jun;15(2):45-52.
    94. Mekky RY, El-Ekiaby NM, Hamza MT, Elemam NM, El-Sayed M, Esmat G, Abdelaziz AI. Mir-194 is a hepatocyte gate keeper hindering HCV entry through targeting CD81 receptor. J Infect. 2015 Jan;70(1):78-87. 
    95. Elhelw DS, Mekky RY, El-Ekiaby N, Ahmed R, Eldin MA, El-Sayed M, Abouelkhair MM, Salah A, Zekri AR, Esmat G, Abdelaziz AI. Predictive prognostic role of miR-181a with discrepancy in the liver and serum of genotype 4 hepatitis C virus patients. Biomed Rep. 2014 Nov;2(6):843-848. 
    96. Saad Y, Shaker O, Nassar Y, Ahmad L, Said M, Esmat G. A polymorphism in the microsomal triglyceride transfer protein can predict the response to antiviral therapy in Egyptian patients with chronic hepatitis C virus genotype 4 infection. Gut Liver. 2014 Nov;8(6):655-61.
    97. Breban R, Arafa N, Leroy S, Mostafa A, Bakr I, Tondeur L, Abdel-Hamid M, Doss W, Esmat G, Mohamed MK, Fontanet A. Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study. Lancet Glob Health. 2014 Sep;2(9):e541-e549
    98. Ismail S, Hafez HA, Darweesh SK, Kamal KH, Esmat G. Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy. Ann Gastroenterol. 2014;27(4):380-386
    99. Mohsen A, Bernier A, LeFouler L, Delarocque-Astagneau E, El-Daly M, El-Kafrawy S, El-Mango S, Abdel-Hamid M, Gadallah M, Esmat G, Mohamed MK, Fontanet A. Hepatitis C virus acquisition among Egyptians: analysis of a 10-year surveillance of acute hepatitis C. Trop Med Int Health. 2015 Jan;20(1):89-97.
    100. Riad SE, El-Ekiaby N, Mekky RY, Ahmed R, El Din MA, El-Sayed M, Abouelkhair MM, Salah A, Zekri AR, Esmat G, Abdelaziz AI. Expression signature of microRNA-155 in hepatitis C virus genotype 4 infection. Biomed Rep. 2015 Jan;3(1):93-97. doi: 10.3892/br.2014.373. Epub 2014 Oct 22. 
    101. Obach D, Yazdanpanah Y, Esmat G, Avihingsanon A, Dewedar S, Durier N, Attia A, Anwar WA, Cousien A, Tangkijvanich P, Eholié SP, Doss W, Mostafa A, Fontanet A, Mohamed MK, Deuffic-Burban S. How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries. Hepatology. 2015 Jul;62(1):31-9. 
    102. Zekri AR, Youssef AS, Bakr YM, Gabr RM, El-Rouby MN, Hammad I, Ahmed EA, Marzouk HA, Nabil MM, Hamed HA, Aly YH, Zachariah KS, Esmat G. Serum biomarkers for early detection of hepatocellular carcinoma associated with HCV infection in egyptian patients. Asian Pac J Cancer Prev. 2015;16(3):1281-7. 
    103. Zekri AR, Youssef AS, Bakr YM, Gabr RM, El-Rouby MN, Hammad I, Ahmed EA, Marzouk HA, Nabil MM, Hamed HA, Aly YH, Zachariah KS, Esmat G. Serum biomarkers for early detection of hepatocellular carcinoma associated with HCV infection in egyptian patients. Asian Pac J Cancer Prev. 2015;16(3):1281-7.
    104. Assal RA, El Tayebi HM, Hosny KA, Esmat G, Abdelaziz AI. A pleiotropic effect of the single clustered hepatic metastamiRs miR-96-5p and miR-182-5p on insulin-like growth factor II, insulin-like growth factor-1 receptor and insulin-like growth factor-binding protein-3 in hepatocellular carcinoma. Mol Med Rep. 2015 Jul;12(1):645-50. doi: 10.3892/mmr.2015.3382. Epub 2015 Feb 24. 
    105. Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M, Samir W, Hammad R, Kersey K, Jiang D, Doehle B, Knox SJ, Massetto B, McHutchison JG, Esmat G. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015 Sep;63(3):581-5. 
    106. Fawzy IO, Hamza MT, Hosny KA, Esmat G, El Tayebi HM, Abdelaziz AI. miR-1275: A single microRNA that targets the three IGF2-mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma. FEBS Lett. 2015 Aug 4;589(17):2257-65.
    107. El-Ekiaby NM, Mekky RY, El Sobky SA, Elemam NM, El-Sayed M, Esmat G, Abdelaziz AI. Epigenetic harnessing of HCV via modulating the lipid droplet-protein, TIP47, in HCV cell models. FEBS Lett. 2015 Aug 4;589(17):2266-73.
    108. Khattab H, Fouad A, Hamza M, Mohey MA, El-Akel W, Ghoneim H, Abul-Fotouh A, Esmat G. Relation of ALT and AST levels to the histopathological changes in liver biopsies of patients with chronic hepatitis C genotype 4. Arab J Gastroenterol. 2015 Jun;16(2):50-3. 
    109. Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: A review. J Adv Res. 2015 May;6(3):301-10. 
    110. Elemam NM, Mekky RY, El-Ekiaby NM, El Sobky SA, El Din MA, Esmat G, Abdelaziz AI. Repressing PU.1 by miR-29a∗ in NK cells of HCV patients, diminishes its cytolytic effect on HCV infected cell models. Hum Immunol. 2015 Sep;76(9):687-94.
    111. El Sobky SA, El-Ekiaby NM, Mekky RY, Elemam NM, Mohey Eldin MA, El-Sayed M, Esmat G, Abdelaziz AI. Contradicting roles of miR-182 in both NK cells and their host target hepatocytes in HCV. Immunol Lett. 2016 Jan;169:52-60. 
    112. Zekri AR, Abdullah D, Osman A, El-Rouby MN, Zayed N, Esmat G, Elakel W, Hafez HA. Epstein-Barr virus and Interleukin-28B polymorphism in the prediction of response to interferon therapy in hepatitis C patients. Arab J Gastroenterol. 2015 Sep-Dec;16(3-4):84-9. 
    113. Nady S, Ezz A, El-Shorbagy A, Esmat G, Mt S. HCV Infection Amplified Th2 Bias and Th17 Responses In Schistosoma-Infected Patients. Egypt J Immunol. 2016 Jan;23(1):87-96
    114. El Tayebi HM, Waly AA, Assal RA, Hosny KA, Esmat G, Abdelaziz AI. Transcriptional activation of the IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma. Oncol Lett. 2015 Nov;10(5):3206-3212. 
    115. Esmat G, Raziky ME, Nabeel MM, Maher R, Zakaria Z. Seroprevalence of HCV among Cairo University students in Egypt. J Med Virol. 2016 Aug;88(8):1384-7.
    116. El Raziky M, Fathalah WF, Zakaria Z, Eldeen HG, Abul-Fotouh A, Salama A, Awad A, Esmat G, Mabrouk M. Predictors of Virological Response in 3,235 Chronic HCV Egyptian Patients Treated with Peginterferon Alpha-2a Compared with Peginterferon Alpha-2b Using Statistical Methods and Data Mining Techniques. J Interferon Cytokine Res. 2016 May;36(5):338-46.
    117. Hashem S, Esmat G, Elakel W, Habashy S, Abdel Raouf S, Darweesh S, Soliman M, Elhefnawi M, El-Adawy M, ElHefnawi M. Accurate Prediction of Advanced Liver Fibrosis Using the Decision Tree Learning Algorithm in Chronic Hepatitis C Egyptian Patients. Gastroenterol Res Pract. 2016;2016:2636390. 
    118. Mostafa A, Shimakawa Y, Medhat A, Mikhail NN, Chesnais CB, Arafa N, Bakr I, El Hoseiny M, El-Daly M, Esmat G, Abdel-Hamid M, Mohamed MK, Fontanet A. Excess mortality rate associated with hepatitis C virus infection: A community-based cohort study in rural Egypt. J Hepatol. 2016 Jun;64(6):1240-6.
    119. Esmat GE, Al Akel W, Abdel Aziz RA, Al Sayed Taha A, Sabry D, Rashed LA, Mostafa A, El Kazaz AY, Ahmed SH. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy. J Interferon Cytokine Res. 2016 Mar;36(3):149-58.
    120. Fawzy IO, Hamza MT, Hosny KA, Esmat G, Abdelaziz AI. Abrogating the interplay between IGF2BP1, 2 and 3 and IGF1R by let-7i arrests hepatocellular carcinoma growth. Growth Factors. 2016 Feb;34(1-2):42-50
    121. Abdelrahman MM, Fawzy IO, Bassiouni AA, Gomaa AI, Esmat G, Waked I, Abdelaziz AI. Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma. Hum Immunol. 2016 Aug;77(8):667-673. 
    122. Medhat E, Esmat G, Hamza E, Abdel Aziz A, Fouad Fathalah W, Darweesh SK, Zakaria Z, Mostafa S. Ophthalmological side effects of interferon therapy of chronic hepatitis C. Hepatobiliary Surg Nutr. 2016 Jun;5(3):209-16.
    123. Salama ZA, Sadek A, Abdelhady AM, Darweesh SK, Morsy SA, Esmat G. Losartan may inhibit the progression of liver fibrosis in chronic HCV patients. Hepatobiliary Surg Nutr. 2016 Jun;5(3):249-55.
    124. Yosry A, Fouad R, Alem SA, Elsharkawy A, El-Sayed M, Asem N, Hassan E, Ismail A, Esmat G. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab J Gastroenterol. 2016 Jun;17(2):78-83.
    125. Shimakawa Y, Bonnard P, El Kassas M, Abdel-Hamid M, Esmat G, Fontanet A. Diagnostic accuracy of the γ-glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4. Gut. 2016 Sep;65(9):1577-8.
    126. Asselah T, Esmat G, Sanai FM, Goulis I, Messinger D, Bakalos G, Waked I. Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies. Adv Ther. 2016 Oct;33(10):1797-1813. 
    127. El-Ekiaby NM, Mekky RY, Riad SE, Elhelw DS, El-Sayed M, Esmat G, Abdelaziz AI. miR-148a and miR-30a limit HCV-dependent suppression of the lipid droplet protein, ADRP, in HCV infected cell models. J Med Virol. 2017 Apr;89(4):653-659.
    128. El Kassas M, Elbaz T, Abd El Latif Y, Esmat G. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Rev Clin Pharmacol. 2016 Nov;9(11):1413-1421. 
    129. Habashy DA, El Tayebi HM, Fawzy IO, Hosny KA, Esmat G, Abdelaziz AI. Interplay between microRNA-17-5p, insulin-like growth factor-II through binding protein-3 in hepatocellular carcinoma. World J Hepatol. 2016 Aug 18;8(23):976-84. 
    130. Yacoub RA, Fawzy IO, Assal RA, Hosny KA, Zekri AN, Esmat G, El Tayebi HM, Abdelaziz AI. miR-34a: Multiple Opposing Targets and One Destiny in Hepatocellular Carcinoma. J Clin Transl Hepatol. 2016 Dec 28;4(4):300-305. doi: 10.14218/JCTH.2016.00031. Epub 2016 Dec 27. 
    131. Eletreby R, Elakel W, Said M, El Kassas M, Seif S, Elbaz T, El Raziky M, Abdel Rehim S, Zaky S, Fouad R, Gamal Eldeen H, Abdo M, Korany M, Yosry A, El Serafy M, El-Sayed MH, ElShazly Y, Waked I, Doss W, Esmat G. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int. 2017 Apr;37(4):534-541.
    132. Negro F, Esmat G. Extrahepatic manifestations in hepatitis C virus infection. J Adv Res. 2017 Mar;8(2):85-87. 
    133. Elsharkawy A, Alem SA, Fouad R, El Raziky M, El Akel W, Abdo M, Tantawi O, AbdAllah M, Bourliere M, Esmat G. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. J Gastroenterol Hepatol. 2017 Sep;32(9):1624-1630.
    134. El Kassas M, Wifi MN, Mahdy R, Afify S, Hafez E, El Latif YA, Ezzat M, El Tahan A, Youssef N, Esmat G. Herpes Zoster reactivation in patients with chronic hepatitis C under treatment with directly acting antiviral agents: A case series. Arab J Gastroenterol. 2017 Mar;18(1):39-41.
    135. Hashem S, Esmat G, Elakel W, Habashy S, Raouf SA, Elhefnawi M, Eladawy M, ElHefnawi M. Comparison of Machine Learning Approaches for Prediction of Advanced Liver Fibrosis in Chronic Hepatitis C Patients. IEEE/ACM Trans Comput Biol Bioinform. 2018 May-Jun;15(3):861-868. 
    136. Waked I, Shiha G, Qaqish RB, Esmat G, Yosry A, Hassany M, Soliman R, Mohey MA, Allam N, Zayed N, Asselah T, Hall C, Redman R, Mobashery N, Doss W. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol. 2016 Sep;1(1):36-44. 
    137. El Kassas M, Elbaz T, Hafez E, Wifi MN, Esmat G. Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection. Expert Opin Drug Discov. 2017 Jun;12(6):635-642. 
    138. Eletreby R, Elakel W, El Raziky M, Esmat G. Response to Real life Egyptian experience of efficacy / safety of Simeprevir\ Sofosbuvir in HCV genotype IV. Liver Int. 2017 May;37(5):766. 
    139. Elsharkawy A, Eletreby R, Fouad R, Soliman Z, Abdallah M, Negm M, Mohey M, Esmat G. Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. Expert Rev Gastroenterol Hepatol. 2017 Aug;11(8):773-778. 
    140. Elhelw DS, Riad SE, Shawer H, El-Ekiaby N, Salah A, Zekri A, Amleh A, Esmat G, Abdelaziz AI. Ectopic delivery of miR-200c diminishes hepatitis C virus infectivity through transcriptional and translational repression of Occludin. Arch Virol. 2017 Nov;162(11):3283-3291.
    141. Abdel Alem S, Elsharkawy A, Fouad R, Adel E, Abdellatif Z, Musa S, Nagy A, Hussein MS, Yosry A, Esmat G. Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience. J Med Virol. 2017 Dec;89(12):2181-2187.
    142. Hafez E, Elbaz T, El Kassas M, Esmat G. A New Potent NS5A Inhibitor in the Management of Hepatitis C Virus: Ravidasvir. Curr Drug Discov Technol. 2018;15(1):24-31.
    143. El Kassas M, Alboraie M, Mostafa A, Ezzat R, El Tahan A, Afify S, Sweedy A, Kabbash I, Esmat G. After successful hepatitis C virus antiviral therapy: It looks that normal alanine aminotransferase level is not the normal. J Clin Lab Anal. 2018 Mar;32(3):e22296.
    144. Elbaz T, Elserafy M, Elakel W, Mohey MA, Abdo M, Hassany M, Mehrez M, Abouelkhair M, Yosry A, Omar A, Waked I, Elsayed MH, Mahran Z, Elshazly Y, Elgarem N, Gaballa A, Doss W, Esmat G. Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. J Interferon Cytokine Res. 2017 Aug;37(8):348-353. 
    145. Ramzy I, Elsharkawy A, Fouad R, Hafez HA, El Raziky M, El Akel W, El-Sayed M, Khattab H, Shehata M, Elsharkawy M, Radwan A, Esmat G. Impact of old Schistosomiasis infection on the use of transient elastography (Fibroscan) for staging of fibrosis in chronic HCV patients. Acta Trop. 2017 Dec;176:283-287.
    146. Ramzy I, Elsharkawy A, Fouad R, Hafez HA, El Raziky M, El Akel W, El-Sayed M, Khattab H, Shehata M, Elsharkawy M, Radwan A, Esmat G. Impact of old Schistosomiasis infection on the use of transient elastography (Fibroscan) for staging of fibrosis in chronic HCV patients. Acta Trop. 2017 Dec;176:283-287. 
    147. Esmat G, Elbaz T, El Raziky M, Gomaa A, Abouelkhair M, Gamal El Deen H, Sabry A, Ashour M, Allam N, Abdel-Hamid M, Nada O, Helmy S, Abdel-Maguid H, Colonno R, Brown N, Ruby E, Vig P, Waked I. Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4. J Hepatol. 2017 Sep 19:S0168-8278(17)32286-9. 
    148. Alboraie M, Schütte K, Khairy M, Elsharkawy M, Asem N, Elghamry F, Shalaby H, Esmat G, Malfertheiner P. Validation of Hepa-index as a non-invasive biomarkers panel for assessment of hepatic fibrosis in Egyptians with chronic hepatitis C. Saudi Med J. 2017 Nov;38(11):1137-1142. 
    149. Nady S, Esmat G. IL-17 Induced The Recruitment and Functional Activity of Granulocytes Isolated from Patients Coinfected with Schistosoma mansoni and Hepatitis C Virus. Egypt J Immunol. 2017 Jan;24(1):9-20. 
    150. Elsharkawy A, Alboraie M, Fouad R, Asem N, Abdo M, Elmakhzangy H, Mehrez M, Khattab H, Esmat G. Establishing ultrasound based transient elastography cutoffs for different stages of hepatic fibrosis and cirrhosis in Egyptian chronic hepatitis C patients. Arab J Gastroenterol. 2017 Dec;18(4):210-215.
    151. Elsharkawy A, El-Raziky M, El-Akel W, El-Saeed K, Eletreby R, Hassany M, El-Sayed MH, Kabil K, Ismail SA, El-Serafy M, Abdelaziz AO, Shaker MK, Yosry A, Doss W, El-Shazly Y, Esmat G, Waked I. Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. J Hepatol. 2018 Apr;68(4):691-698. 
    152. Gamil M, Alboraie M, El-Sayed M, Elsharkawy A, Asem N, Elbaz T, Mohey M, Abbas B, Mehrez M, Esmat G. Novel scores combining AFP with non-invasive markers for prediction of liver fibrosis in chronic hepatitis C patients. J Med Virol. 2018 Jun;90(6):1080-1086
    153. El Kassas M, Omran D, Elsaeed K, Alboraie M, Elakel W, El Tahan A, Abd El Latif Y, Nabeel MM, Korany M, Ezzat S, El-Serafy M, ElShazly Y, Doss W, Esmat G. Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience. J Interferon Cytokine Res. 2018 Feb;38(2):81-85. 
    154. Cordie A, Salama A, El-Sharkawy M, El-Nahaas SM, Khairy M, Elsharkawy A, Hassany M, Esmat G. Comparing the efficiency of Fib-4, Egy-score, APRI, and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C. J Med Virol. 2018 Jun;90(6):1106-1111. 
    155. El Kassas M, Elbaz T, Elsharkawy A, Omar H, Esmat G. HCV in Egypt, prevention, treatment and key barriers to elimination. Expert Rev Anti Infect Ther. 2018 Apr;16(4):345-350. 
    156. Zekri AN, El Deeb S, Bahnassy AA, Badr AM, Abdellateif MS, Esmat G, Salama H, Mohanad M, El-Dien AE, Rabah S, Abd Elkader A. Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions. World J Gastroenterol. 2018 Mar 21;24(11):1228-1238. 
    157. Elhelw DS, Riad SE, Shawer H, El-Ekiaby N, Salah A, Zekri A, Amleh A, Esmat G, Abdelaziz AI. Correction to: Ectopic delivery of miR-200c diminishes hepatitis C virus infectivity through transcriptional and translational repression of Occludin. Arch Virol. 2018 May;163(5):1405. 
    158. Riad SE, Elhelw DS, Shawer H, El-Ekiaby N, Salah A, Zekri A, Esmat G, Amleh A, Abdelaziz AI. Disruption of Claudin-1 Expression by miRNA-182 Alters the Susceptibility to Viral Infectivity in HCV Cell Models. Front Genet. 2018 Mar 20;9:93. 
    159. Shiha G, Esmat G, Hassany M, Soliman R, Elbasiony M, Fouad R, Elsharkawy A, Hammad R, Abdel-Razek W, Zakareya T, Kersey K, Massetto B, Osinusi A, Lu S, Brainard DM, McHutchison JG, Waked I, Doss W. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut. 2019 Apr;68(4):721-728. 
    160. Fouad R, Elbaz T, Abdel Alem S, Elsharkawy A, Negm M, Khairy M, Hassany M, Cordie A, El Akel W, Esmat G. Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients. Eur J Gastroenterol Hepatol. 2018 Aug;30(8):882-887. 
    161. Hassany M, Elsharkawy A, Maged A, Mehrez M, Asem N, Gomaa A, Mostafa Z, Abbas B, Soliman M, Esmat G. Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact. Eur J Gastroenterol Hepatol. 2018 Aug;30(8):876-881. 
    162. El Kassas M, Shimakawa Y, Ali-Eldin Z, Funk AL, Wifi MN, Zaky S, El-Raey F, Esmat G, Fontanet A. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data. Liver Int. 2018 Dec;38(12):2159-2169. 
    163. El Kassas M, Alboraie M, Omran D, Salaheldin M, Wifi MN, ElBadry M, El Tahan A, Ezzat S, Moaz E, Farid AM, Omar H, Abouelkhair M, Afify S, Elsaeed K, Shazly Y, Doss W, Esmat G. An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. Expert Rev Gastroenterol Hepatol. 2018 Dec;12(12):1265-1272. 
    164. Filomena A, Göpfert JC, Duffy D, Pol S, Abdel-Hamid M, Esmat G, Fontanet A, Albert ML, Joos TO, Schneiderhan-Marra N. Study of the Humoral Immune Response towards HCV Genotype 4 Using a Bead-Based Multiplex Serological Assay. High Throughput. 2017 Oct 30;6(4):15. 
    165. Waked I, Esmat G, Fouad R, Allam N, Hassany M, Mohey M, Shiha G, Soliman R, Qaqish RB, Hall C, Alami NN, Kopecky-Bromberg S, Mobashery N. Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study. J Med Virol. 2018 Nov;90(11):1739-1744. 
    166. Mattar MM, Zekri AN, Hussein N, Morsy H, Esmat G, Amin MA. Polymorphisms of base-excision repair genes and the hepatocarcinogenesis. Gene. 2018 Oct 30;675:62-68. 
    167. El-Nahaas SM, Fouad R, Elsharkawy A, Khairy M, Elhossary W, Anwar I, Abdellatif Z, Maher RM, Bekheet N, Esmat G. High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience. Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1194-1199
    168. El Kassas M, Alboraie M, Elsaeed K, Ahmed Y, El Tahan A, Alhaddad O, Salaheldin M, Kabbash I, El Badry M, Fathy T, El-Serafy M, ElShazly Y, Doss W, Esmat G. Real-Life Efficacy of 5 Different Antiviral Regimens for Treatment of Chronic Hepatitis C With Normal Liver Enzymes. Am J Ther. 2018 Nov/Dec;25(6):e776-e779. 
    169. Elbaz T, Abdo M, Omar H, Hassan EA, Zaghloul AM, Abdel-Samiee M, Moustafa A, Qawzae A, Gamil M, Esmat G. Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection. J Med Virol. 2019 Feb;91(2):272-277. 
    170. Esmat G, El-Sayed MH, Hassany M, Doss W, Waked I; National Committee for the Control of Viral Hepatitis. One step closer to elimination of hepatitis C in Egypt. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):665. 
    171. Hamed AE, Elsahar M, Elwan NM, El-Nakeep S, Naguib M, Soliman HH, Ahmed Aboubakr A, AbdelMaqsod A, Sedrak H, Assaad SN, Elwakil R, Esmat G, Salh S, Mostafa T, Mogawer S, Sadek SE, Saber MM, Ezelarab H, Mahmoud AA, Sultan S, El Kassas M, Kamal E, ElSayed NM, Moussa S. Managing diabetes and liver disease association. Arab J Gastroenterol. 2018 Dec;19(4):166-179. 
    172. Hamed AE, Elwan N, Naguib M, Elwakil R, Esmat G, El Kassas M, Abd-Elsalam S, Moussa S. Diabetes Association with Liver Diseases: An Overview for Clinicians. Endocr Metab Immune Disord Drug Targets. 2019;19(3):274-280. 
    173. El-Bendary M, Neamatallah M, Elalfy H, Besheer T, El-Setouhy M, Kasim N, Abou El-Khier NT, Kamel E, Eladl AH, El-Waseef A, Abdel-Aziz AF, Esmat G. Association of interferon gamma gene polymorphism and susceptibility to hepatitis C virus infection in Egyptian patients: A multicenter, family-based study. JGH Open. 2017 Dec 19;1(4):140-147. 
    174. Yosry A, Gamal Eldeen H, Medhat E, Mehrez M, Zayed N, Elakel W, Abdelmoniem R, Kaddah M, Abdelaziz A, Esmat G, El-Serafy M, Doss W. Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience. J Med Virol. 2019 Apr;91(4):668-676.
    175. Waly AA, El-Ekiaby N, Assal RA, Abdelrahman MM, Hosny KA, El Tayebi HM, Esmat G, Breuhahn K, Abdelaziz AI. Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma. Front Physiol. 2019 Jan 24;9:1918.
    176. Hamed AE, Elsahar M, Elwan NM, El-Nakeep S, Naguib M, Soliman HH, Aboubakr AA, AbdelMaqsod A, Sedrak H, Assaad SN, Elwakil R, Esmat G, Salh S, Mostafa T, Mogawer S, Sadek SE, Saber MM, Ezelarab H, Mahmoud AA, Sultan S, El Kassas M, Kamal E, ElSayed NM, Moussa S; Jury, Reviewers and Advisory Board: Sherif Abdelfattah, Samir Helmy ASSAAD-KHALIL, Ahmed Ali Elgarem, Rawia Khater, Amr Helmi, Hisham Elborlsy, Abdelhamid Attia (President of the Arab Federation Of Evidence-Based Medicine). Managing diabetes and liver disease association: Practice guidelines from the Egyptian Association for the Study of Liver and Gastrointestinal Disease (EASLGD). Arab J Gastroenterol. 2019 Mar;20(1):61-63. 
    177. Fouad R, Elsharkawy A, Abdel Alem S, El Kassas M, Alboraie M, Sweedy A, Afify S, Abdellatif Z, Khairy M, Esmat G. Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. Eur J Gastroenterol Hepatol. 2019 Sep;31(9):1129-1134.
    178. Mekky RY, El-Ekiaby N, El Sobky SA, Elemam NM, Youness RA, El-Sayed M, Hamza MT, Esmat G, Abdelaziz AI. Epigallocatechin gallate (EGCG) and miR-548m reduce HCV entry through repression of CD81 receptor in HCV cell models. Arch Virol. 2019 Jun;164(6):1587-1595. 
    179. El-Garem H, AbdAllah M, Omar H, Cordie A, Abdel Alem S, Mohey Eldin Elzahry MA, Ghaith D, Abou El-Soud NH, Kamal W, Elsharkawy A, Esmat G. DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV. Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):693-698. 
    180. El-Bendary M, Neamatallah M, Elalfy H, Besheer T, Kamel E, Mousa H, Eladl AH, El-Setouhy M, El-Gilany AH, El-Waseef A, Esmat G. HLA Class II-DRB1 Alleles with Hepatitis C Virus Infection Outcome in Egypt: A Multicentre Family-based Study. Ann Hepatol. 2019 Jan-Feb;18(1):68-77. 
    181. Darweesh SK, Elsaeed K, Omar H, El Raziky M, Elakel W, Elserafy M, Ismail SA, Gomaa AA, Mehrez M, El Kassas M, Abdullah M, Shaker MK, Esmat G, El Shazly Y, Doss W, Waked I. High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study. Expert Rev Gastroenterol Hepatol. 2019 Sep;13(9):907-914.
    182. El Kassas M, Elbaz T, Salaheldin M, Abdelsalam L, Kaseb A, Esmat G. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review. J Adv Res. 2019 Mar 7;17:43-48.
    183. Abdel Alem S, Elsharkawy A, El Akel W, Abdelaziz AO, Salama RM, El-Sayed MH, El Kassas M, Anees M, Shedeed M, Abdelsalam F, Ziada DH, El Shazly Y, El-Serafy M, Waked I, Esmat G, Doss W. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. Expert Rev Gastroenterol Hepatol. 2019 Oct;13(10):1009-1016. 
    184. Alboraie M, Elhossary W, Aly OA, Abbas B, Abdelsalam L, Ghaith D, Shady Z, Gaber Y, Adel E, Peura D, Armstrong D, Esmat G; special interest group; Egyptian Association for Study of Gastrointestinal Diseases and Liver (E A S G L D). Egyptian recommendations for management of Helicobacter pylori infection: 2018 report. Arab J Gastroenterol. 2019 Sep;20(3):175-179. 
    185. Neamatallah M, El-Bendary M, Elalfy H, Besheer T, El-Maksoud MA, Elhammady D, Abed S, Elegezy M, Kandeel L, Eldeib D, Mousa N, Abd El-Hafeez M, El-Gilany AH, Esmat G. Impact of Toll-like Receptors 2(TLR2) and TLR 4 Gene Variations on HCV Susceptibility, Response to Treatment and Development of Hepatocellular Carcinoma in Cirrhotic HCV Patients. Immunol Invest. 2020 May;49(4):462-476.
    186. El-Khayat H, Kamal EM, Mahmoud H, Gomaa A, Ebeid B, Sameh Y, Hasseb A, El Raziky M, El Serafy M, Doss W, Esmat G, Fouad Y, Attia D. Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors’ failure: efficacy and safety of different regimens. Eur J Gastroenterol Hepatol. 2020 Mar;32(3):440-446. 
    187. Nasser MZ, Zayed NA, Mohamed AM, Attia D, Esmat G, Khairy A. Circulating microRNAs (miR-21, miR-223, miR-885-5p) along the clinical spectrum of HCV-related chronic liver disease in Egyptian patients. Arab J Gastroenterol. 2019 Dec;20(4):198-204.
    188. Hatzakis A, Lazarus JV, Cholongitas E, Baptista-Leite R, Boucher C, Busoi CS, Deuffic-Burban S, Chhatwal J, Esmat G, Hutchinson S, Malliori MM, Maticic M, Mozalevskis A, Negro F, Papandreou GA, Papatheodoridis GV, Peck-Radosavljevic M, Razavi H, Reic T, Schatz E, Tozun N, Younossi Z, Manns MP. Securing sustainable funding for viral hepatitis elimination plans. Liver Int. 2020 Feb;40(2):260-270. 
    189. Elkabany ZA, Hamza RT, Ismail EAR, Elsharkawy A, Yosry A, Musa S, Khalaf MA, Elgawesh RM, Esmat G. Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter. Eur J Gastroenterol Hepatol. 2020 Aug;32(8):1008-1016. 
    190. Eletreby R, El-Serafy M, Anees M, Kasem G, Salama M, Elkhouly R, Hamdy M, Abdel Haleem H, Kamal E, Abdel-Razek W, Salama R, Elshenawy M, Shafeek A, Hassany M, El-Sayed MH, El-Shazly Y, Esmat G. Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. Liver Int. 2020 Apr;40(4):797-805. 
    191. Cordie A, Elsharkawy A, Abdel Alem S, Meshaal S, El Akel W, Abdellatif Z, Kamal W, Al Askalany M, Kamel S, Abdel Aziz H, Kandeel A, Esmat G. Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection. Trans R Soc Trop Med Hyg. 2020 Apr 8;114(4):232-240. 
    192. Abdel-Razek W, Hassany M, El-Sayed MH, El-Serafy M, Doss W, Esmat G, Waked I. Hepatitis C Virus in Egypt: Interim Report From the World’s Largest National Program. Clin Liver Dis (Hoboken). 2020 Jan 29;14(6):203-206
    193. Waked I, Esmat G, Elsharkawy A, El-Serafy M, Abdel-Razek W, Ghalab R, Elshishiney G, Salah A, Abdel Megid S, Kabil K, El-Sayed MH, Dabbous H, El Shazly Y, Abo Sliman M, Abou Hashem K, Abdel Gawad S, El Nahas N, El Sobky A, El Sonbaty S, El Tabakh H, Emad E, Gemeah H, Hashem A, Hassany M, Hefnawy N, Hemida AN, Khadary A, Labib K, Mahmoud F, Mamoun S, Marei T, Mekky S, Meshref A, Othman A, Ragab O, Ramadan E, Rehan A, Saad T, Saeed R, Sharshar M, Shawky H, Shawky M, Shehata W, Soror H, Taha M, Talha M, Tealaab A, Zein M, Hashish A, Cordie A, Omar Y, Kamal E, Ammar I, AbdAlla M, El Akel W, Doss W, Zaid H. Screening and Treatment Program to Eliminate Hepatitis C in Egypt. N Engl J Med. 2020 Mar 19;382(12):1166-1174.
    194. Soliman Z, El Kassas M, Elsharkawy A, Elbadry M, Hamada Y, ElHusseiny R, M El-Nahaas S, Fouad R, Esmat G, Abdel Alem S. Improvement of platelet in thrombocytopenic HCV patients after treatment with direct-acting antiviral agents and its relation to outcome. Platelets. 2020 Apr 6:1-8. 
    195. Esmat G, Elbaz T, Elsharkawy A, Abdullah M, El Kassas M. Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt. Expert Rev Anti Infect Ther. 2020 Jul;18(7):637-642. 
    196. Shousha HI, Said M, ElAkel W, ElShafei A, Esmat G, Waked E, Elsayed MH, Doss W, Elrazky M, Mehrez M, Hassany M, Zeyada D, Anis M, Alserafy M. Assessment of facility performance during mass treatment of chronic hepatitis C in Egypt: Enablers and obstacles. J Infect Public Health. 2020 Sep;13(9):1322-1329. 
    197. Elhendawy M, Abo-Ali L, Abd-Elsalam S, Hagras MM, Kabbash I, Mansour L, Atia S, Esmat G, Abo-ElAzm AR, El-Kalla F, Kobtan A. HCV and HEV: two players in an Egyptian village, a study of prevalence, incidence, and co-infection. Environ Sci Pollut Res Int. 2020 Sep;27(27):33659-33667. 
    198. Hashem S, ElHefnawi M, Habashy S, El-Adawy M, Esmat G, Elakel W, Abdelazziz AO, Nabeel MM, Abdelmaksoud AH, Elbaz TM, Shousha HI. Machine Learning Prediction Models for Diagnosing Hepatocellular Carcinoma with HCV-related Chronic Liver Disease. Comput Methods Programs Biomed. 2020 Nov;196:105551. 
    199. El-Sayed M, Abdellatif Z, Elsharkawy A, El Kassas M, Abd Elmoniem R, Marzouk A, Fouad R, Esmat G, Abdel Alem S. Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy. Infection. 2020 Dec;48(6):913-922. 
    200. Cordie A, El-Kotamy MT, Esmat G. Antiretroviral therapy optimisation in the time of COVID-19: Is it really different in North and South Africa? South Afr J HIV Med. 2020 Jul 30;21(1):1118. 
    201. Eletreby R, Anees M, Naguib M, Kobtan A, Helmy A, Khalaf N, Mansour S, Hassany M, El Akel W, Hashem A, Doss W, Esmat G. The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents. Expert Rev Gastroenterol Hepatol. 2021 Jan;15(1):103-110. 
    202. Hamid S, Alvares da Silva MR, Burak KW, Chen T, Drenth JPH, Esmat G, Gaspar R, LaBrecque D, Lee A, Macedo G, McMahon B, Ning Q, Reau N, Sonderup M, van Leeuwen DJ, Armstrong D, Yurdaydin C. WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. J Clin Gastroenterol. 2021 Jan;55(1):1-11.
    203. Mohamed R, Wanis H, Zebachi S, El-Kotamy MT, Esmat G, Cordie A. COVID-19 crisis effect on HIV service delivery in Egypt: Hard times or blessings in disguise? South Afr J HIV Med. 2020 Dec 9;21(1):1170.